Joint MSU/UofM IP acquired by OncoArendi Therapeutics
OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan
March 11, 2022
– Option to in-license and develop small molecule leads against a novel target for the treatment of fibrotic diseases
– Strengthens pipeline and reinforces OncoArendi’s strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF)
11 March 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate RNA and unexplored protein targets to treat multiple incurable diseases, announces it has entered into an option-to-license agreement with Innovation Partnerships at the University of Michigan (U-M) to develop novel small molecule inhibitors of an undisclosed target, for the treatment of fibrotic diseases. The novel inhibitors were generated and initially validated as a result of a long-standing research collaboration with Michigan State University (MSU). U-M entered in the option-to-license agreement with OncoArendi on behalf of both U-M and MSU.